CRON Stock Analysis: Buy, Sell, or Hold?
CRON - Cronos Group Inc. Common Share
$2.65
-0.10 (-3.47%)
▼
5d:
+4.13%
30d:
-1.31%
90d:
+1.73%
BUY
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Accumulation
CRON is down 3.8% this week, but smart money is accumulating calls. Top strike: $2 2026-07-17 with 10,689 OI. Call ratio: 91% View Scanner →
Strength: 6.0/10
Get Alerted When CRON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRON shows positive signals but monitor for confirmation. Market pricing in 5.5% decline. Moderate conviction.
💡 BUY OPPORTUNITY: CRON shows positive signals but monitor for confirmation. Market pricing in 5.5% decline. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRON is currently trading at $2.65, which is considered fair relative to its 30-day fair value range of $2.57 to $2.73. From a valuation perspective, the stock is trading at a discount (Forward PE: 18.8) compared to its historical average (22.2). Remarkably, the market is currently pricing in an annual earnings decline of 5.5% over the next few years. This pessimistic expectation contrasts with the company's recent 128.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CRON is in a strong uptrend. Immediate support is located at $2.52, while resistance sits at $2.94. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: CRON has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $2.30. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRON is in a strong uptrend. Immediate support is located at $2.52, while resistance sits at $2.94. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: CRON has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $2.30. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.57 -
$2.73
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.0%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BEARISH: Trading 16.2% above Wall St target ($2.30)
Trading Range Analysis
30-Day Trading Range
$2.57 -
$2.73
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.52
Resistance Level
$2.94
Current Trend
Strong Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.77
Wall Street Target
$2.30
(-16.2%)
Revenue Growth (YoY)
40.1%
Earnings Growth (YoY)
128.6%
Profit Margin
-1.1%
Valuation Discount vs History
-5.5% cheaper
PE vs Historical
18.8 vs 22.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.5%
(market-implied from PE analysis)
1-Year Target
$2.59
(-6%)
2-Year Target
$2.45
(-11%)
3-Year Target
$2.31
(-16%)
3-Yr Target (if PE normalizes)
(PE: 19→22)
$2.74
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 21.9%)
$5.82
(+113%)
Base:
(SPY PE: 18.8, Growth: 21.9%)
$4.96
(+81%)
Bear:
(PE: 16.0, Growth: 21.9%)
$4.22
(+54%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.8 to 22.2
Stabilization Target:
$3.24
(+18.3%)
PE Expansion Potential:
+18.3%
Share & Embed Analysis
Last updated: May 15, 2026 1:03 PM ET
Data refreshes hourly during market hours. Next update: 2:03 PM
Data refreshes hourly during market hours. Next update: 2:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 56 HOLD |
Advanced CRON Option Strategies
Professional options setups generated by AI based on today's CRON price and gamma walls.
